CD4⁺ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.

According to the percentage of CD4 + T cells in the CIKs population before they received the second CIK adoptive therapy, we divided these patients equally into high group (The mean value was 50.87%), intermediate group (37.77%), and low group (25.06%), and found that the intermediate group had a better progression-free survival (PFS) as compared to the other groups and a favorable trend for overall survival (OS) (Fig. 1A, B ).

also in 1,335 other papers